Overview

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

Status:
Completed

Trial end date:
2018-07-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with active intestinal Behcet's disease who are refractory to conventional therapies.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Korea, Ltd., Korea

Treatments:

Infliximab